NRX Pharmaceuticals, Inc.
NRXP · XNASCIK 1719406fmd_12NWFX7R4EMEK6KYX78W0462DCManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2017 to Jun 30, 2026, 35 periods
| Line item | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | – | – | 0 | 0 | 1 |
| Net interest income | 1 | 1 | 0 | – | – | – | – | – |
| Cost of revenue | – | – | – | – | – | – | 0 | 1 |
| Gross profit | – | – | – | – | – | – | 0 | 1 |
| Research and development | – | – | 11 | 20 | 17 | 13 | 6 | 4 |
| Selling, general and administrative | – | – | – | – | – | – | 14 | 13 |
| Total operating expenses | 1 | 1 | 51 | 116 | 44 | 28 | 19 | – |
| Operating income | (1) | (1) | (51) | (116) | (44) | (28) | (19) | (16) |
| Interest expense | – | – | 0 | 0 | – | 0 | 0 | 1 |
| Interest and investment income | – | – | – | – | – | 0 | 0 | 0 |
| Other non-operating income (expense) | 1 | 1 | (0) | 23 | 5 | (2) | (7) | (12) |
| Income before taxes | 0 | 0 | (52) | (93) | (40) | – | – | – |
| Income tax expense | 0 | 0 | 0 | – | – | 0 | 0 | 0 |
| Net income from continuing operations | 0 | 0 | (52) | – | – | – | – | – |
| Net income | 0 | 0 | (52) | (93) | (40) | (30) | (25) | (29) |
| Net income to common shareholders | (1) | (0) | (52) | (349) | (40) | (30) | (25) | – |